Genelux

Genelux Book Value per Share

The Book Value per Share of Genelux (GNLX) as of Nov 17, 2026 is 0.26 USD. In the previous year, Book Value per Share was 0.59 USD — a change of -56.06% (lower).

Book Value per Share

0.26USD

YoY

-56.06%

Last updated:

Book Value per Share of Genelux is 2025 0.26 USD. Book Value per Share of Genelux was 2024 0.59 USD. It decreases by -56.06% lower compared to the previous year.

The Genelux Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2019
-0.55 USD
Jan 1, 2020
-0.51 USD
Jan 1, 2021
-0.74 USD
Jan 1, 2022
-0.80 USD
Jan 1, 2023
0.44 USD
Jan 1, 2024
0.59 USD
Jan 1, 2025
0.26 USD
The Genelux Book Value per Share history
YEARBook Value per ShareYoY
0.26USD-56.06%
0.59USD+34.93%
0.44USD-154.42%
-0.80USD+8.07%
-0.74USD+46.15%
-0.51USD-8.69%
-0.55USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp develops and markets oncolytic viral immunotherapies, including Olvi-Vec, a modified vaccinia virus strain for platinum-resistant ovarian cancer, and V2ACT, a personalized anti-cancer therapy enhancing T cell activity. The company focuses on Phase II trials for Olvi-Vec in solid tumors and offers V-VET1, a veterinary oncolytic virus for animal health. Products target patients with solid tumor types and animal health applications, with clinical development driven by the firm's pipeline. The company generates revenue through the development and commercialization of its drug candidates, including Olvi-Vec, V2ACT, and V-VET1, targeting both human oncology and veterinary markets. Clinical trial phases and product development stages define its current focus, with Olvi-Vec in Phase II for ovarian cancer and V-VET1 in veterinary applications. The firm operates with a 15-employee structure, emphasizing pipeline advancement without publicized commercial sales yet. Genelux Corp's product portfolio includes Olvi-Vec for human solid tumors, V2ACT as a personalized immunotherapy, and V-VET1 for animal health. The company's revenue model relies on advancing these therapies through clinical trials, with no current commercial sales disclosed. The firm is positioned to address unmet needs in oncology, particularly in platinum-resistant cancers, and veterinary oncology through its viral-based approaches. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

Book Value per Share of Genelux is 0.26 USD in 2025.

Book Value per Share of Genelux changed from 0.59 USD to 0.26 USD, representing a -56.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Genelux since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genelux

All Key Metrics — Genelux